Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Sagamihara
Clinical trial register · Japan

Clinical Trials in Sagamihara, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC8 Sanofi5 Novartis Pharmaceuticals3 Bayer3 Bristol-Myers Squibb3
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Sagamihara

51 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
Novartis Pharmaceuticals
Phase 3
770
Sagamihara, Kashihara, Bunkyo Ku
2026-03-24
Recruiting
Bristol-Myers Squibb
Phase 3
850
Nagoya, Kobe, Nishinomiya, Sagamihara, Yokohama, Sendai, Hirakata, Sakai
2026-03-16
Recruiting
Genmab
Phase 2
240
Sagamihara, Yokohama, Kyoto, Nagoya, Saitama, Sakai, Chūō, Tokyo
2026-01-30
Recruiting
Amicus Therapeutics
Phase 3
8
Sagamihara
2026-01-08
Recruiting
Janssen Research & Development, LLC
Phase 3
800
Bunkyō City, Hirakata, Kanazawa, Kobe, Sagamihara, Sunto Gun, Yokohama
2025-12-19
Recruiting
Novartis Pharmaceuticals
Phase 3
300
Chikushino-shi, Kitakyushu, Kamakura, Sagamihara, Bunkyo Ku
2025-10-03
Recruiting
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
200
Chiba, Fuchū, Niigata, Sagamihara, Sanda-shi, Sendai
2025-09-30
Recruiting
Boston Scientific Corporation
Not applicable
1,616
Sapporo, Sagamihara, Mitaka, Kochi
2025-08-21
Active, closed
Bayer
Phase 3
36
Kurume, Himeji, Kobe, Tsukuba, Morioka, Sagamihara, Yokohama, Nankoku
2025-06-30
Recruiting
Kitasato University
Not applicable
300
Sagamihara
2025-06-25
Recruiting
Pfizer
Phase 2
620
Kasugai, Matsudo, Sakura, Sapporo, Koga, Sagamihara, Yokohama, Tsu
2025-06-19
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
DrugsCetuximab·Docetaxel
Revolution Medicines, Inc.
Phase 3
590
Nagoya, Toyoake-shi, Kashiwa-shi, Matsuyama, Sapporo, Akashi, Kanazawa, Sagamihara
2025-05-06
Recruiting
Mirati Therapeutics Inc.
Phase 3
630
Nagoya, Sapporo, Kanazawa, Sagamihara, Yokohama, Sendai, Kashihara, Kurashiki
2025-04-24
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 1
35
Nagoya, Kashiwa, Kurume, Nishinomiya, Sagamihara, Yokohama, Nankoku, Kyoto
2025-04-21
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Nagoya, Kashiwa, Matsuyama, Sapporo, Kahoku-gun, Isehara, Kawasaki, Sagamihara
2025-03-16
Active, closed
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis
Alumis Inc
Phase 3
1,680
Nagoya, Fukuoka, Asahikawa, Ibaraki, Kagoshima, Sagamihara, Yokohama, Kanagawa
2025-01-08
Recruiting
Institut de Recherches Internationales Servier
Phase 3
48
Yoshida-gun, Higashi-ku, Fukuoka-city, Fukuoka, Himeji-city, Hyogo, Isehara-city, Kanagawa, Musashino-city, Tokyo, Sagamihara
2024-12-03
Active, closed
UCB Biopharma SRL
Phase 3
13
Fuchu-shi, Ōbu, Sagamihara
2024-10-08
Recruiting
Bristol-Myers Squibb
Phase 3
1,000
Nakamura-ku,Nagoya, Kashiwa, Kitakyushu, Kurume, Fukuyama-shi, Sapporo, Sagamihara, Yokohama
2024-10-07
Active, closed
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
349
Chiba, Fuchū, Gifu, Niigata, Sagamihara, Sanda-shi, Sendai
2024-10-02
Recruiting
Bayer
Phase 3
444
Nagoya, Kashiwa, Sapporo, Himeji, Kobe, Sagamihara, Sendai, Hirakata
2024-08-28
Recruiting
Colorado Prevention Center
Phase 3
2,600
Sapporo, Isehara, Sagamihara, Kyoto, Sendai, Osaka, Suita, Ōta-ku
2024-08-20
Active, closed
Novartis Pharmaceuticals
Phase 3
162
Fukuoka, Asahikawa, Kita-gun, Sagamihara, Yokohama, Nagano, Kawachi-Nagano, Osaka
2024-06-28
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,530
Nagoya, Kashiwa, Ōta, Sapporo, Isehara, Kawasaki, Sagamihara, Yokohama
2024-06-24
Active, closed
Cytokinetics
Phase 2/3
65
Kagoshima, Osaka, Sagamihara, Suita, Tokyo
2024-05-29
Active, closed
Sanofi
Phase 3
1,541
Chitose, Obihiro, Sapporo, Kobe, Sagamihara, Yokohama, Miyagi-gun, Sendai
2024-05-08
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Nagoya, Kashiwa, Sapporo, Isehara, Kawasaki, Sagamihara, Yokohama, Tsu
2024-04-14
Active, closed
Samsung Bioepis Co., Ltd.
Phase 3
555
Himeji, Iwakuni, Izumi, Kawachi-Nagano, Kobe, Kochi, Sagamihara, Tachikawa
2024-03-12
Active, closed
Sanofi
Phase 3
943
Kōriyama, Asahikawa, Himeji, Sagamihara, Higashi-Matsuyama, Kodaira, Chiba, Fukuoka
2023-12-27
Active, closed
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
NCT06046222Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
NS Pharma, Inc.
Phase 2
45
Chuo-ku, Chiba-shi, Kitakyushu, Sapporo, Sagamihara, Yokohama, Sendai, Habikino, Kawagoe
2023-12-20
Active, closed
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
NCT05973773Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
DrugZipalertinib
Taiho Oncology, Inc.
Phase 3
285
Nagoya, Hirosaki-Shi, Fukuoka, Sagamihara, Yokohama, Kumamoto, Sendai, Okayama
2023-12-18
Active, closed
Sanofi
Phase 3
1,655
Kōriyama, Asahikawa, Sapporo, Yahaba, Sagamihara, Higashi-Matsuyama, Kodaira, Tachikawa
2023-12-13
Active, closed
Gilead Sciences
Phase 2
176
Hyōgo, Jonan-ku, Minatoku, Mitaka-shi, Nagasaki, Ōita, Sagaken, Sagamihara
2023-12-05
Recruiting
International Cardiac Amyloidosis Registry
NCT06894290Cardiac Amyloidosis
Leiden University Medical Center
Observational
300
Sagamihara
2023-06-30
By invitation
Eli Lilly and Company
Phase 3
333
Toyoake, Fukuyama, Hiroshima, Asahikawa, Sagamihara, Kyoto, Ina, Okayama
2023-03-09
Active, closed
Bristol-Myers Squibb
Phase 2/3
230
Kitakyushu-shi, Sapporo, Amagasaki, Sagamihara, Sendai, Shinagawa-ku, Osaka
2022-12-14
Active, closed
Sanofi
Phase 2/3
1,856
Chitose, Obihiro, Sapporo, Sagamihara, Yokohama, Habikino, Sakai, Iruma
2022-08-22
Active, closed
Merck Sharp & Dohme LLC
Phase 3
342
Nishinomiya, Kawasaki, Sagamihara, Suita, Hidaka, Shinjuku-ku, Chiba, Fukuoka
2021-06-18
Active, closed
Merck Sharp & Dohme LLC
Phase 3
808
Nagoya, Hirosaki, Tsukuba, Kanazawa, Sagamihara, Yokohama, Sendai, Hamamatsu
2021-04-21
Recruiting
Mirati Therapeutics Inc.
Phase 2/3
626
Nagoya, Toon-shi, Fukushima, Akashi, Nishinomiya-Shi, Sagamihara, Sendai, Nagasaki
2020-12-02
Active, closed
Bayer
Phase 3
402
Nagoya, Asahi, Sakura, Maebashi, Sapporo, Kobe, Higashiibaraki, Sagamihara
2020-10-20
Active, closed
PharmaEssentia
Phase 3
174
Tōon, Sagamihara, Tsu, Miyazaki, Hirakata, Sayama, Suita, Izunokuni
2020-08-25
Active, closed
Daiichi Sankyo Co., Ltd.
Phase 2
25
Nagoya, Sagamihara, Sendai, Hidaka, Hiroshima, Kumamoto, Kyoto, Osaka
2020-07-08
Active, closed
SyncAV Post-Market Trial
NCT04100148Congestive Heart Failure
Abbott Medical Devices
Not applicable
1,686
Chiba, Nishinomiya, Kawasaki, Sagamihara
2019-10-03
Active, closed
Sanofi
Observational
1,860
Sagamihara, Yokohama, Tsu, Habikino, Fuchū, Fukuoka, Fukuyama-shi, Hiroshima
2019-08-15
Recruiting
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
NCT04064060Myelodysplastic Syndromes (MDS), Beta-thalassemia, Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
DrugLuspatercept
Celgene
Phase 3
665
Nagoya, Kamogawa, Matsuyama, Ōgaki, Himeji, Hitachi, Sagamihara, Sendai
2019-08-12
Active, closed
Merck Sharp & Dohme LLC
Phase 3
595
Kashiwa, Tsukuba, Kawasaki, Sagamihara, Yokosuka, Sendai, Tomitake, Kashihara
2019-07-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,240
Nagoya, Kashiwa, Sapporo, Nishinomiya, Sagamihara, Kumamoto, Hidaka, Kitaadachi-gun
2018-12-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,397
Hirosaki, Tōon, Tsukuba, Kawasaki, Sagamihara, Yokosuka, Kashihara, Hamamatsu
2018-12-24
Active, closed
Biotronik SE & Co. KG
Observational
3,030
Fukuoka, Hiroshima, Kanagawa, Sagamihara, Saitama, Tokyo, Toyoake
2018-05-14
Active, closed
Regeneron Pharmaceuticals
Phase 1
146
Nagoya, Kurume, Ōta, Kobe, Kanazawa, Sagamihara, Yokohama, Sasebo
2017-06-21
Rows per page Showing 1–51 of 51
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/sagamihara

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 51 of those studies with a site in Sagamihara.

How many clinical trials are recruiting in Sagamihara?

22 of the 51 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 28 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Sagamihara), 51 studies
PhaseStudiesRecruitingShare
Phase 3321562.7%
Phase 27313.7%
Phase 2/3417.8%
Not applicable325.9%
Observational315.9%
Phase 1203.9%

Most active sponsors

Lead sponsors with the most studies (Sagamihara)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC83
Sanofi50
Bayer31
Bristol-Myers Squibb32
Novartis Pharmaceuticals32
Mirati Therapeutics Inc.22
Teva Branded Pharmaceutical Products R&D LLC21
Abbott Medical Devices10
Alumis Inc10
Amicus Therapeutics11
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.